A Study to Assess the Efficacy and Safety of Zipalertinib Versus Placebo for Adjuvant Treatment in Participants With Stage IB-IIIA NSCLC With Uncommon EGFR Mutations, Following Complete Tumor Resection

Clinical trial NCT07128199 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT07128199
Sponsor: Taiho Oncology, Inc.
Status: ACTIVE_NOT_RECRUITING
Phase: Phase 3
Study type: INTERVENTIONAL

NSCLC, Stage IB-IIIA Lung Cancer Adjuvant Post-surgical EGFR Exon 20 Early Stage Lung Cancer Uncommon EGFR Mutations

Start date: 2025-12-22
Primary completion: 2029-10-01
Enrollment: 360

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.